Loading...
XPAROSE
Market cap159mUSD
Dec 24, Last price  
7.06EUR
1D
0.71%
1Q
-10.41%
Jan 2017
-0.28%
IPO
-33.40%
Name

OSE Immunotherapeutics SA

Chart & Performance

D1W1MN
XPAR:OSE chart
P/E
—
P/S
68.96
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.74%
Rev. gr., 5y
-38.07%
Revenues
2m
-87.83%
0004,000383,0006,682,00024,456,00025,952,00010,418,00026,306,00018,302,0002,227,000
Net income
-23m
L+29.52%
-1,436,000-250,000-2,835,000-5,584,00020,666,000-10,503,0005,490,000-4,652,000-16,555,000-16,850,000-17,760,000-23,003,000
CFO
-20m
L+8.28%
-1,393,000-236,000-1,937,000-4,614,000684,000-7,996,0001,077,0008,971,000-19,550,000-9,919,000-18,252,000-19,764,000
Earnings
Mar 25, 2025

Profile

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.
URL
https://ose-immuno.com/
IPO date
Mar 30, 2015
Employees
67
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,227
-87.83%
18,302
-30.43%
26,306
152.51%
Cost of revenue
17,158
36,543
42,533
Unusual Expense (Income)
NOPBT
(14,931)
(18,241)
(16,227)
NOPBT Margin
Operating Taxes
(219)
(5,694)
(4,708)
Tax Rate
NOPAT
(14,712)
(12,547)
(11,519)
Net income
(23,003)
29.52%
(17,760)
5.40%
(16,850)
1.78%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,657
6
265
BB yield
-13.92%
0.00%
-0.14%
Debt
Debt current
7,261
3,976
2,367
Long-term debt
42,430
40,817
34,766
Deferred revenue
1,000
3,586
3,965
Other long-term liabilities
429
524
710
Net debt
31,019
18,649
2,973
Cash flow
Cash from operating activities
(19,764)
(18,252)
(9,919)
CAPEX
(232)
(274)
(472)
Cash from investing activities
(507)
26
(827)
Cash from financing activities
13,324
10,267
14,957
FCF
(14,091)
(12,087)
(13,163)
Balance
Cash
18,672
25,620
33,579
Long term investments
524
581
Excess cash
18,561
25,229
32,845
Stockholders' equity
(18,827)
(32,404)
(17,555)
Invested Capital
88,032
110,247
102,919
ROIC
ROCE
EV
Common stock shares outstanding
19,562
18,457
18,155
Price
4.28
-35.88%
6.68
-35.07%
10.28
42.78%
Market cap
83,726
-32.04%
123,203
-33.99%
186,633
66.63%
EV
114,900
141,852
189,606
EBITDA
(11,460)
(14,684)
(13,621)
EV/EBITDA
Interest
2,269
1,372
836
Interest/NOPBT